Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/1034—Isolating an individual clone by screening libraries
  • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• • C—CHEMISTRY; METALLURGY
  • C40—COMBINATORIAL TECHNOLOGY
  • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
  • C40B40/00—Libraries per se, e.g. arrays, mixtures
  • C40B40/04—Libraries containing only organic compounds
  • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
  • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Definitions

• Massively parallel (or "next generation”) sequencing platforms are rapidly transforming data collection and analysis in genome, epigenome and transcriptome research.
• Certain sequencing platforms such as those marketed by lllumina®, Ion TorrentTM, RocheTM, and Life TechnologiesTM, involve solid phase amplification of target polynucleotides of unknown sequence. Solid phase amplification of these polynucleotides is typically performed by first ligating known adapter sequences to each end of a target polynucleotide. The double-stranded polynucleotide is then denatured to form a single-stranded template molecule that is immobilized on the solid substrate. The adapter sequence on the 3' end of the template is hybridized to an extension primer, and amplification is performed by extending the primer.
• a disadvantage of ligation-based approaches for sequencing adapter addition is the number of steps involved, including the enzymatic and wash steps that are needed to prepare the target polynucleotide before amplification can be initiated.
• unused adapter molecules must be separated from the ligated polynucleotides before proceeding to the amplification, so as to avoid unwanted amplification of adapters that have not been attached to the target polynucleotides.
• the unused adapter molecules may also hybridize to the amplification primers, preventing efficient hybridization of the primers to the template molecules and subsequent extension.
• Methods of preparing a next generation sequencing (NGS) library from a ribonucleic acid (RNA) sample are provided. Aspects of the methods include combining the RNA sample with a first strand cDNA primer and a template switch oligonucleotide under first strand cDNA synthesis conditions, where one of the first strand cDNA primer and the template switch oligonucleotide includes a first post-tagmentation amplification, e.g., PCR amplification, primer binding domain.
• NGS next generation sequencing
• the resultant product is subjected to amplification conditions sufficient to produce a double stranded cDNA, which product is then tagmented with a transposome that includes a second post-tagmentation amplification, e.g., PCR amplification, primer binding domain.
• amplification conditions such as PCR amplification conditions, using first and second amplification primers that include sequencing platform adapter constructs to produce a NGS library.
• aspects of the invention further include compositions produced by the methods and kits that find use in practicing the methods.
• FIG. 1 schematically illustrates an embodiment of the methods of the disclosure.
• FIG. 2 schematically illustrates a template switch-based method for producing a product double stranded cDNA according to one embodiment of the present disclosure.
• FIG. 3A schematically illustrates the preparation of a NGS library from a RNA sample according to one embodiment of the present disclosure.
• FIG. 3B schematically illustrates the assembly of a transposome according to an embodiment of the present disclosure.
• FIG. 3C schematically illustrates a nucleic acid of the NGS library produced according to the example embodiment illustrated in panel A.
• FIG. 3D schematically illustrates the preparation of a NGS library from a RNA sample according to one embodiment of the present disclosure that employs a single transposome.
• FIGS. 4A, 4B and 4C show FPKM (Fragments Per Kilobase of exon per Million reads) data upon sequencing product double stranded cDNAs produced according to the embodiment illustrated in FIG. 2.
• FIG. 5 is a flow diagram of an experiment designed to test the NGS library preparation method illustrated in FIG. 3A.
• FIG. 6 provides mapping statistics for the libraries produced according to the experimental design shown in FIG. 5.
• FIGS. 7A and 7B show graphs indicating normalized read counts per gene as determined by DESeq2 analysis of mapped libraries.
• FIGS. 8A and 8B show heat maps representing the Pearson correlations of regularized log-transformed read-counts (rlog) for libraries derived from mouse brain samples (FIG. 8A) and human brain samples (FIG. 8B).
• FIGS. 9A and 9B show graphs for gene body coverage analysis for unpooled and pooled libraries.
• FIGS. 10A to 10D show results of various aspects of a single transposome mediated NGS library production protocol (illustrated in FIG3D) from single cells.
• FIG. 11A provides graphical representations of the results from an experiment configured to determine the effect of a unique molecular identifier (UMI) on an Oligo dT primer, e.g., as illustrated in FIG. 1 1 B.
• UMI unique molecular identifier
• a domain refers to a stretch or length of a nucleic acid made up of a plurality of nucleotides, where the stretch or length provides a defined function to the nucleic acid.
• domains include primer binding domains, hybridization domains, barcode domains (such as source barcode domains), unique molecular identifier domains, NGS adaptor domains, NGS indexing domains, etc. While the length of a given domain may vary, in some instances the length ranges from 2 to 100 nt, such as 5 to 50 n, e.g., 5 to 30 nt.
• Amplification primer binding domains are domains that are configured to bind via hybridization to an amplification primer.
• Pre-tagmentation amplification primer binding domains are domains which are configured to bind to pre-tagmentation amplification primers during an amplification that occurs before a tagmentation step, e.g., a cDNA amplification protocol which occurs prior to a tagemention step.
• Post-tagmentation amplification primer binding domains are domains which are configured to bind to post-tagmentation amplification primers during an amplification that occurs after a tagmentation step, e.g., a tagmented sample amplification protocol which occurs after to a tagmentation step.
• a barcode domain is a domain that serves as an identifier of a nucleic acid. Barcode domains may vary, wherein examples include RNA source barcode domains, e.g., cell barcode domains, host barcode domains, etc.; container barcode domains, such as plate or well barcode domains; in-line barcode domains, indexing barcode domains, etc.
• UMIs Unique Molecular Identifiers
• UMIs are randomers of varying length, e.g., ranging in length in some instances from 6 to12 nts, that can be used for counting of individual molecules of a given molecular species. Counting is achieved by attaching UMIs from a diverse pool of UMIs to individual molecules of a target of interest such that each individual molecule receives a unique UMI. By counting individual transcript molecules, PCR bias can be reduced during NGS library prep and a more quantitative understanding of the sample population can be achieved. See e.g., U.S. Patent No. 8,835,358; Fu et al., "Molecular Indexing Enables
• complementary refers to a nucleotide sequence that base- pairs by non-covalent bonds to all or a region of a target nucleic acid (e.g., a template RNA or other region of the double stranded product nucleic acid).
• a target nucleic acid e.g., a template RNA or other region of the double stranded product nucleic acid.
• adenine (A) forms a base pair with thymine (T), as does guanine (G) with cytosine (C) in DNA.
• thymine is replaced by uracil (U).
• U uracil
• A is complementary to T and G is complementary to C.
• A is complementary to U and vice versa.
• complementary refers to a nucleotide sequence that is at least partially complementary.
• the term “complementary” may also encompass duplexes that are fully complementary such that every nucleotide in one strand is complementary to every nucleotide in the other strand in corresponding positions.
• a nucleotide sequence may be partially complementary to a target, in which not all nucleotides are complementary to every nucleotide in the target nucleic acid in all the corresponding positions.
• a primer may be perfectly (i.e., 100%) complementary to the target nucleic acid, or the primer and the target nucleic acid may share some degree of complementarity which is less than perfect (e.g., 70%, 75%, 85%, 90%, 95%, 99%).
• hybridization conditions means conditions in which a primer specifically hybridizes to a region of the target nucleic acid (e.g., a template RNA or other region of the double stranded product nucleic acid). Whether a primer specifically hybridizes to a target nucleic acid is determined by such factors as the degree of complementarity between the polymer and the target nucleic acid and the temperature at which the hybridization occurs, which may be informed by the melting temperature (T M ) of the primer.
• T M melting temperature refers to the temperature at which half of the primer-target nucleic acid duplexes remain hybridized and half of the duplexes dissociate into single strands.
• T M melting temperature
• the first strand cDNA primer includes two amplification binding sites, one for pre-tagmentation amplification (e.g., cDNA amplification) and one for post- tagmentation amplification, such as library amplification (e.g., first post-tagmentation amplification site) and the template switch oligonucleotide includes a complementary pre- tagmentation amplification e.g., PCR amplification, primer binding domain.
• pre-tagmentation amplification e.g., cDNA amplification
• post- tagmentation amplification such as library amplification (e.g., first post-tagmentation amplification site)
• the template switch oligonucleotide includes a complementary pre- tagmentation amplification e.g., PCR amplification, primer binding domain.
• the resultant product is subjected to amplification, e.g., PCR amplification, with a single primer complementary to the pre-tagmentation amplification binding site found on both the first strand cDNA synthesis primer and the template switch oligonucleotide under conditions sufficient to produce a double stranded cDNA.
• the resultant product is then tagmented with a transposome that includes a second post-tagmentation amplification primer binding domain.
• the tagmented sample is then subjected to amplification conditions using two primers that complement the first and second post-tagmentation amplification sites introduced in the cDNA by synthesis and tagmentation, respectively, to produce a NGS library.
• aspects of the invention further include compositions produced by the methods and kits that find use in practicing the methods.
• NGS libraries produced by methods of the invention are those whose nucleic acid members include a partial or complete sequencing platform adapter sequence at their termini useful for sequencing using a sequencing platform of interest.
• Sequencing platforms of interest include, but are not limited to, the HiSeq , MiSeq and Genome Analyzer sequencing systems from lllumina®; the Ion PGMTM and Ion ProtonTM sequencing systems from Ion TorrentTM; the PACBIO RS II Sequel system from Pacific Biosciences, the SOLiD sequencing systems from Life TechnologiesTM, the 454 GS FLX+ and GS Junior sequencing systems from Roche, the MinlONTM system from Oxford Nanopore, or any other sequencing platform of interest.
• an RNA target (squiggly (blue) line) can be contacted with a first primer (e.g., a cDNA synthesis primer) that includes a pre- tagmentation amplification primer binding domain (i.e., pre-tagmentation amplification primer binding site (PBS) (indicated in green with a star at terminus) and a first post-tagmentation primer binding domain domain (i.e., first post-tagmentation amplification PBS (indicated in yellow) and an RNA binding domain or site (e.g., oligo dT, (indicated in pink)).
• a pre- tagmentation amplification primer binding domain i.e., pre-tagmentation amplification primer binding site (PBS) (indicated in green with a star at terminus)
• PBS pre-tagmentation amplification primer binding site
• first post-tagmentation primer binding domain domain domain i.e., first post-tagmentation amplification PBS (indicated
• First strand synthesis and template switching is performed as illustrated, e.g., using the SMART-Seq v4 template switch oligonucleotide (Takara Bio USA, Inc, Mountain View CA)(indicated by a 5' green domain and a 3' XXXXX domain).
• the template switch oligonucleotide includes a pre-tagmentation amplification primer binding domain (i.e., pre- tagmentation amplification PBS).
• the pre-tagmentation amplification PBS can be the same as the pre-tagmentation amplification PBS on the cDNA synthesis primer.
• the double-stranded cDNA can be contacted with transposon complexes that include one or more second post-tagmentation amplification primer binding domains (i.e., post-tagmentation amplification primer binding sites, e.g., TnRP1 and/or TnRP2).
• the second post-tagmentation amplification primer binding domains can be randomly attached to fragment ends of the double-stranded cDNA library according to tagmentation and transposon mechanisms of action.
• the resulting tagmentation fragments are diagrammed in FIG. 1.
• the fragments can be amplified with a primer that binds to the second post-tagmentation amplification primer binding domain (e.g., orange box) and a primer that binds to the first post-tagmentation amplification primer binding domain (e.g., yellow box).
• These two primers can include additional sequencing adaptor sequences, such as the P5 and P7 sequences, as well as the forward and reverse indexes (e.g., i5, i7) for sequencing, as desired.
• the use of the first and second post-tagmentation amplification primers allows for selective amplification of an end (e.g., 3' end) fragment. Other fragments are not amplified either because the correct primers are missing, or due to suppression effects during PCR.
• RNA sample e.g., a mRNA sample
• a first strand cDNA synthesis primer i.e., a first strand CDS primer
• a template switch oligonucleotide i.e., a TSO
• reverse transcriptase a reverse transcriptase
• dNTPs dNTPs
• first strand cDNA synthesis conditions e.g., conditions sufficient to produce a double stranded product nucleic acid that includes the template RNA and the template switch oligonucleotide each hybridized to adjacent regions of a first strand complementary deoxyribonucleic acid (cDNA), where the first strand cDNA includes the first strand cDNA synthesis primer at its 5' end and a newly synthesized length or portion that is complementary to domains found in the template RNA and template switch oligonucleotide, wherein this newly synthesized domain is covalently bonded to the 3' end of the first strand
• condition sufficient to produce a double stranded product nucleic acid is meant reaction conditions that permit polymerase-mediated extension of a 3' end of the first strand cDNA primer hybridized to the template RNA, template switching of the polymerase to the template switch oligonucleotide, and continuation of the extension reaction using the template switch oligonucleotide as the template.
• Achieving suitable reaction conditions may include selecting reaction mixture components, concentrations thereof, and a reaction temperature to create an environment in which the polymerase is active and the relevant nucleic acids in the reaction interact (e.g., hybridize) with one another in the desired manner.
• the reaction mixture may include buffer components that establish an appropriate pH, salt concentration (e.g., KCI concentration), metal cofactor concentration (e.g., Mg 2+ or Mn 2+ concentration), and the like, for the extension reaction and template switching to occur.
• buffer components that establish an appropriate pH, salt concentration (e.g., KCI concentration), metal cofactor concentration (e.g., Mg 2+ or Mn 2+ concentration), and the like, for the extension reaction and template switching to occur.
• Other components may be included, such as one or more nuclease inhibitors (e.g., an RNase inhibitor and/or a DNase inhibitor), one or more additives for facilitating amplification/replication of GC rich sequences (e.g., GC-MeltTM reagent (Takara Bio USA, Inc.
• betaine e.g., betaine, DMSO, ethylene glycol, 1 ,2-propanediol, or combinations thereof
• molecular crowding agents e.g., polyethylene glycol, Ficoll, dextran, or the like
• enzyme-stabilizing components e.g., DTT, or TCEP, present at a final concentration ranging from 1 to 10 mM (e.g., 5 rtiM)
• any other reaction mixture components useful for facilitating polymerase-mediated extension reactions and template- switching.
• the reaction mixture can have a pH suitable for the primer extension reaction and template-switching.
• the pH of the reaction mixture ranges from 5 to 9, such as from 7 to 9, including from 8 to 9, e.g., 8 to 8.5.
• the reaction mixture includes a pH adjusting agent. pH adjusting agents of interest include, but are not limited to, sodium hydroxide, hydrochloric acid, phosphoric acid buffer solution, citric acid buffer solution, and the like.
• the pH of the reaction mixture can be adjusted to the desired range by adding an appropriate amount of the pH adjusting agent.
• the temperature range suitable for production of the double stranded product nucleic acid may vary according to factors such as the particular polymerase employed, the melting temperatures of any optional primers employed, etc.
• the polymerase is a reverse transcriptase (e.g., an MMLV reverse transcriptase) and the reaction mixture conditions sufficient to produce the double stranded product nucleic acid include bringing the reaction mixture to a temperature ranging from 4° C to 72° C, such as from 16° C to 70° C, e.g., 37° C to 50° C, such as 40° C to 45° C, including 42° C.
• the template ribonucleic acid (RNA) within the RNA sample may be a polymer of any length composed of ribonucleotides, e.g., 10 nts or longer, 20 nts or longer, 50 nts or longer, 100 nts or longer, 500 nts or longer, 1000 nts or longer, 2000 nts or longer, 3000 nts or longer, 4000 nts or longer, 5000 nts or longer or more nts.
• ribonucleotides e.g., 10 nts or longer, 20 nts or longer, 50 nts or longer, 100 nts or longer, 500 nts or longer, 1000 nts or longer, 2000 nts or longer, 3000 nts or longer, 4000 nts or longer, 5000 nts or longer or more nts.
• the template ribonucleic acid is a polymer composed of ribonucleotides, e.g., 10 nts or less, 20 nts or less, 50 nts or less, 100 nts or less, 500 nts or less, 1000 nts or less, 2000 nts or less, 3000 nts or less, 4000 nts or less, or 5000 nts or less, 10,000 nts or less, 25,000 nts or less, 50,000 nts or less, 75,000 nts or less, 100,000 nts or less.
• ribonucleotides e.g., 10 nts or less, 20 nts or less, 50 nts or less, 100 nts or less, 500 nts or less, 1000 nts or less, 2000 nts or less, 3000 nts or less, 4000 nts or less, or 5000 nt
• the template RNA may be any type of RNA (or sub-type thereof) including, but not limited to, a messenger RNA (mRNA), a microRNA (miRNA), a small interfering RNA (siRNA), a transacting small interfering RNA (ta-siRNA), a natural small interfering RNA (nat-siRNA), a ribosomal RNA (rRNA), a transfer RNA (tRNA), a small nucleolar RNA (snoRNA), a small nuclear RNA (snRNA), a long non-coding RNA (IncRNA), a non-coding RNA (ncRNA), a transfer-messenger RNA (tmRNA), a precursor messenger RNA (pre-mRNA), a small Cajal body-specific RNA (scaRNA), a piwi-interacting RNA (piRNA), an endoribonuclease-prepared siRNA (esiRNA), a small temporal RNA (stRNA), a signal recognition
• the RNA sample that includes the template RNA may be combined into the reaction mixture in an amount sufficient for producing the product nucleic acid.
• the RNA sample is combined into the reaction mixture such that the final concentration of RNA in the reaction mixture is from 1 fg/ ⁇ to 10 ⁇ g/ ⁇ L, such as from 1 pg/ ⁇ to 5 ⁇ g/ ⁇ L, such as from 0.001 ⁇ g/ ⁇ L to 2.5 ⁇ g/ ⁇ L, such as from 0.005 ⁇ g/ ⁇ L to 1 ⁇ g/ ⁇ L, such as from 0.01 ⁇ g/ ⁇ L to 0.5 ⁇ g/ ⁇ L, including from 0.1 ⁇ g/ ⁇ L to 0.25 ⁇ g/ ⁇ L.
• the RNA sample that includes the template RNA is isolated from a single cell. In other aspects, the RNA sample that includes the template RNA is isolated from 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, 20 or more, 50 or more, 100 or more, or 500 or more cells, such as 750 or more cells, 1 ,000 or more cells, 2,000 or more cells, including 5,000 or more cells. According to certain embodiments, the RNA sample that includes the template RNA is isolated from 500 or less, 100 or less, 50 or less, 20 or less, 10 or less, 9, 8, 7, 6, 5, 4, 3, or 2 cells.
• the template RNA may be present in any nucleic acid sample of interest, including but not limited to, a nucleic acid sample isolated from a single cell, a plurality of cells (e.g., cultured cells), a tissue, an organ, or an organism (e.g., bacteria, yeast, or higher eukaryotic organisms, such as a plant, or a mouse, or a worm, or the like).
• the nucleic acid sample is isolated from a cell(s), tissue, organ, and/or the like of a mammal (e.g., a human, a rodent (e.g., a mouse), or any other mammal of interest).
• the sample may be isolated from a bodily compartment suitable for use in diagnosis, such as blood, urine, saliva, platelets, microvesicles, exosomes, serum, or other bodily fluids.
• the nucleic acid sample is isolated from a source other than a mammal, such as bacteria, yeast, insects (e.g., drosophila), amphibians (e.g., frogs (e.g., Xenopus)), viruses, plants, or any other non- mammalian nucleic acid sample source.
• kits for isolating RNA from such sources are known in the art.
• kits for isolating RNA from a source of interest such as the NucleoSpin®, NucleoMag® and NucleoBond® RNA isolation kits by Clontech Laboratories, Inc. (Mountain View, CA) - are commercially available.
• the RNA is isolated from a fixed biological sample, e.g., formalin-fixed, paraffin-embedded (FFPE) tissue.
• FFPE formalin-fixed, paraffin-embedded
• RNA from FFPE tissue may be isolated using commercially available kits - such as the NucleoSpin® FFPE RNA kits by Clontech Laboratories, Inc. (Mountain View, CA).
• the subject methods include producing the template RNA from a precursor RNA.
• an RNA sample from a source of interest may be subjected to shearing/fragmentation, e.g., to generate a sample that includes template RNAs that are shorter in length as compared to precursor non-sheared RNAs (e.g., full-length mRNAs) in the original sample.
• the RNA may be used directly from the lysed cell by placing the cell in a suitable buffer (e.g., a hypotonic solution), optionally in the presence of detergent (e.g.
• RT reaction components may then be added directly to the lysate without further isolation to generate cDNA from the cellular RNA.
• the template RNA may be generated by a shearing/fragmentation strategy including, but not limited to, passing the sample one or more times through a micropipette tip or fine-gauge needle, nebulizing the sample, sonicating the sample (e.g., using a focused-ultrasonicator by Covaris, Inc.
• RNA-shearing enzymes e.g., RNA-shearing enzymes, or by enzymatic digestions, e.g., with restriction enzymes or other endonucleases appropriate for the polynucleotides of interest
• chemical based fragmentation e.g., using divalent cations, fragmentation buffer (which may be used in combination with heat) or any other suitable approach for shearing/fragmenting a precursor RNA to generate a shorter template RNA.
• the template RNA generated by shearing/fragmentation of a starting nucleic acid sample has a length of from 10 to 20 nts, from 20 to 30 nts, from 30 to 40 nts, from 40 to 50 nts, from 50 to 60 nts, from 60 to 70 nts, from 70 to 80 nts, from 80 to 90 nts, from 90 to 100 nts, from 100 to 150 nts, from 150 to 200 nts, from 200 to 250 nts in length, or from 200 to 1000 nts or even from 1000 to 10,000 nts in length, for example, as appropriate for the sequencing platform chosen.
• producing a template RNA may include adding nucleotides to an end of the precursor RNA.
• the precursor RNA is a non-polyadenylated RNA (e.g., a microRNA, small RNA, or the like), and producing the template RNA includes adenylating (e.g., polyadenylating) the precursor RNA.
• Adenylating the precursor RNA may be performed using any convenient approach.
• the adenylation is performed enzymatically, e.g., using Poly(A) polymerase or any other enzyme suitable for catalyzing the incorporation of adenine residues at the 3' terminus of the precursor RNA.
• Reaction mixtures for carrying out the adenylation reaction may include any useful components, including but not limited to, a polymerase, a buffer (e.g., a Tris-HCL buffer), one or more metal cations (e.g., MgCI 2 , MnCI 2 , or combinations thereof), a salt (e.g., NaCI), one or more enzyme-stabilizing components (e.g., DTT), ATP, and any other reaction components useful for facilitating the adenylation of a precursor RNA.
• a buffer e.g., a Tris-HCL buffer
• metal cations e.g., MgCI 2 , MnCI 2 , or combinations thereof
• a salt e.g., NaCI
• enzyme-stabilizing components e.g., DTT
• ATP any other reaction components useful for facilitating the adenylation of a precursor RNA.
• the adenylation reaction may be carried out at a temperature (e.g., 30°C-50°C, such as 37°C) and pH (e.g., pH 7 - pH 8.5, such as pH 7.9) compatible with the polymerase being employed, e.g., polyA polymerase.
• a temperature e.g., 30°C-50°C, such as 37°C
• pH e.g., pH 7 - pH 8.5, such as pH 7.9
• Other approaches for adding nucleotides to a precursor RNA include ligation-based strategies, where an RNA ligase (e.g., T4 RNA ligase) catalyzes the covalent joining of a defined sequence to an end (e.g., the 3' end) of the precursor RNA to produce a template RNA.
• an RNA ligase e.g., T4 RNA ligase
• the reverse transcriptase may be a Moloney Murine Leukemia Virus reverse transcriptase (MMLV RT) or a Bombyx mori reverse transcriptase (e.g., Bombyx mori R2 non-LTR element reverse transcriptase).
• MMLV RT Moloney Murine Leukemia Virus reverse transcriptase
• Bombyx mori reverse transcriptase e.g., Bombyx mori R2 non-LTR element reverse transcriptase
• Polymerases capable of template switching that find use in practicing the subject methods are commercially available and include SMARTScribeTM reverse transcriptase available from Takara Bio USA, Inc. (Mountain View, CA).
• a mix of two or more different polymerases is added to the reaction mixture, e.g., for improved processivity, proof-reading, and/or the like.
• the polymer is one that is heterologous relative to the template, or source thereof.
• a polymerase having terminal transferase activity incorporates 10 or less, such as 5 or less (e.g., 3) additional nucleotides at the 3' end of the nascent DNA strand. All of the nucleotides may be the same (e.g., creating a homonucleotide stretch at the 3' end of the nascent strand) or at least one of the nucleotides may be different from the other(s).
• the terminal transferase activity of the polymerase results in the addition of a homonucleotide stretch of 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the same nucleotides (e.g., all dCTP, all dGTP, all dATP, or all dTTP).
• the terminal transferase activity of the polymerase results in the addition of a homonucleotide stretch of 10 or less, such as 9, 8, 7, 6, 5, 4, 3, or 2 (e.g., 3) of the same nucleotides.
• the polymerase is an MMLV reverse transcriptase (MMLV RT).
• MMLV RT incorporates additional nucleotides (predominantly dCTP, e.g., three dCTPs) at the 3' end of the nascent DNA strand.
• additional nucleotides may be useful for enabling hybridization between the 3' end of the template switch oligonucleotide and the 3' end of the nascent DNA strand, e.g., to facilitate template switching by the polymerase from the template RNA to the template switch oligonucleotide.
• the template switch oligonucleotide may have a 3' hybridization domain complementary to the homonucleotide stretch to enable hybridization between the 3' end of the template switch oligonucleotide and the 3' end of the nascent cDNA strand.
• the template switch oligonucleotide may have a 3' hybridization domain complementary to the heteronucleotide stretch to enable hybridization between the 3' end of the template switch oligonucleotide and the 3' end of the nascent cDNA strand.
• the reaction mixture further includes a first strand cDNA primer.
• the primer includes two or more domains.
• the primer may include a first (e.g., 3') domain that hybridizes to the template RNA and a second (e.g., 5') domain that does not hybridize to the template RNA.
• the sequence of the first and second domains may be independently defined or arbitrary.
• the first domain has a defined sequence (e.g., an oligo dT sequence or an RNA specific sequence) or an arbitrary sequence (e.g., a random sequence, such as a random hexamer sequence) and the sequence of the second domain is defined, e.g., an pre-tagmentation amplification primer binding domain, such as PCR primer binding domain (i.e., pre-tagmentation amplification primer binding site).
• a defined sequence e.g., an oligo dT sequence or an RNA specific sequence
• an arbitrary sequence e.g., a random sequence, such as a random hexamer sequence
• the sequence of the second domain is defined, e.g., an pre-tagmentation amplification primer binding domain, such as PCR primer binding domain (i.e., pre-tagmentation amplification primer binding site).
• the second domain includes a nucleotide sequence that is the same as a nucleotide sequence present in the template switch oligonucleotide, e.g., where the pre-tagmentation amplification primer binding domains are the same and the first and second pre-tagmentation amplification primers share identical.
• the second domain includes a nucleotide sequence that is different from a nucleotide sequence present in the template switch oligonucleotide, e.g., where the sequences of the pre-tagmentation amplification primer binding domains are different and bind to amplification primers of corresponding different sequences.
• the sequence includes all or a component of a sequencing platform adapter construct.
• sequencing platform adapter construct is meant a nucleic acid construct that includes at least a portion of a nucleic acid domain (e.g., a sequencing platform adapter nucleic acid sequence) utilized by a sequencing platform of interest, such as a sequencing platform provided by lllumina® (e.g., the HiSeqTM, MiSeqTM and/or Genome AnalyzerTM sequencing systems); Ion TorrentTM (e.g., the Ion PGMTM and/or Ion ProtonTM sequencing systems); Pacific Biosciences (e.g., the PACBIO RS II sequencing system); Life TechnologiesTM (e.g., a SOLiD sequencing system); Roche (e.g., the 454 GS FLX+ and/or GS Junior sequencing systems); or any other sequencing platform of interest.
• lllumina® e.g., the HiSeqTM, MiSeqTM and/or Genome AnalyzerTM sequencing systems
• a sequencing platform adapter construct includes one or more nucleic acid domains selected from: a domain (e.g., a "capture site” or “capture sequence”) that specifically binds to a surface-attached sequencing platform oligonucleotide (e.g., the P5 or P7 oligonucleotides attached to the surface of a flow cell in an lllumina® sequencing system); a sequencing primer binding domain (e.g., a domain to which the Read 1 or Read 2 primers of the lllumina® platform may bind); a barcode domain (e.g., a domain that uniquely identifies the sample source of the nucleic acid being sequenced to enable sample multiplexing by marking every molecule from a given sample with a specific barcode or "tag”); a barcode sequencing primer binding domain (a domain to which a primer used for sequencing a barcode binds); a molecular identification domain (e.g., a molecular index tag, such as a randomized
• a sequencing platform adapter domain when present, may include one or more nucleic acid domains of any length and sequence suitable for the sequencing platform of interest.
• the nucleic acid domains are from 4 to 200 nts in length.
• the nucleic acid domains may be from 4 to 100 nts in length, such as from 6 to 75, from 8 to 50, or from 10 to 40 nts in length.
• the sequencing platform adapter construct includes a nucleic acid domain that is from 2 to 8 nucleotides in length, such as from 9 to 15, from 16 to 22, from 23 to 29, or from 30 to 36 nts in length.
• the nucleic acid domains may have a length and sequence that enables a polynucleotide (e.g., an oligonucleotide) employed by the sequencing platform of interest to specifically bind to the nucleic acid domain, e.g., for solid phase amplification and/or sequencing by synthesis of the cDNA insert flanked by the nucleic acid domains.
• a polynucleotide e.g., an oligonucleotide
• Example nucleic acid domains include the P5 (5'-AATGATACGGCGACCACCGA-3')(SEQ ID NO:01), P7 (5'- CAAGCAGAAGACGGCATACGAGAT-3')(SEQ ID NO:02), Read 1 primer (5'- ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3')(SEQ ID NO:03) and Read 2 primer (5'- GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3')(SEQ ID NO:04) domains employed on the lllumina®-based sequencing platforms.
• the first strand cDNA primer also includes a post-tagmentation amplification primer binding domain, which domain may be a unique domain in the primer or partially or completely overlap with another domain of the primer, such as the RP2 domain, so long as that domain is compatible with respect to the over protocol being performed.
• a post-tagmentation amplification primer binding domain which domain may be a unique domain in the primer or partially or completely overlap with another domain of the primer, such as the RP2 domain, so long as that domain is compatible with respect to the over protocol being performed.
• nucleotide sequences of nucleic acid domains useful for sequencing on a sequencing platform of interest may vary and/or change over time.
• Adapter sequences are typically provided by the manufacturer of the sequencing platform (e.g., in technical documents provided with the sequencing system and/or available on the manufacturer's website). Based on such information, the sequence of any sequencing platform adapter domains of the template switch oligonucleotide, first strand cDNA primer, amplification primers, and/or the like, may be designed to include all or a portion of one or more nucleic acid domains in a configuration that enables sequencing the nucleic acid insert (corresponding to the template RNA) on the platform of interest.
• the first strand cDNA primer may include one or more nucleotides (or analogs thereof) that are modified or otherwise non-naturally occurring.
• the primer may include one or more nucleotide analogs (e.g., LNA, FANA, 2'-0-Me RNA, 2'-fluoro RNA, or the like), linkage modifications (e.g., phosphorothioates, 3'-3' and 5'-5' reversed linkages), 5' and/or 3' end modifications (e.g., 5' and/or 3' amino, biotin, DIG, phosphate, thiol, dyes, quenchers, etc.), one or more fluorescently labeled nucleotides, or any other feature that provides a desired functionality to the primer that primes cDNA synthesis.
• nucleotide analogs e.g., LNA, FANA, 2'-0-Me RNA, 2'-fluoro RNA, or the like
• linkage modifications e.g.
• the first strand cDNA primer includes a polymerase blocking modification that prevents a polymerase using the region corresponding to the primer as a template from polymerizing a nascent strand beyond the modification.
• Useful modifications include, but are not limited to, an abasic lesion (e.g., a tetrahydrofuran derivative), a nucleotide adduct, an iso-nucleotide base (e.g., isocytosine, isoguanine, and/or the like), and any combination thereof.
• an abasic lesion e.g., a tetrahydrofuran derivative
• nucleotide adduct e.g., an iso-nucleotide base
• iso-nucleotide base e.g., isocytosine, isoguanine, and/or the like
• Such blocking modifications may be included in any of the nucleic acid reagents used when practicing the methods of the present disclosure, including first strand cDNA primer, the template switch oligonucleotide, first and second amplification, e.g., PCR, primers used for amplifying the first-strand cDNA to produce the product double stranded cDNA, amplification primers used for PCR amplification of tagmentation products, and any combination thereof.
• primers employed in methods of the invention such as amplification, e.g., PCR, primers, include a ligation block.
• Ligation blocks of interest that may be present in a given primer, as desired, include but are not limited to: amine, inverted T, and Biotin-TEG.
• template switch oligonucleotide an oligonucleotide template to which a polymerase switches from an initial template (e.g., a template RNA) during a nucleic acid polymerization reaction.
• Oligonucleotides may contain ribonucleotide monomers (i.e., may be oligoribonucleotides or "RNA oligonucleotides”) or deoxyribonucleotide monomers (i.e., may be oligodeoxyribonucleotides or "DNA oligonucleotides”). Oligonucleotides may be 10 to 20, 21 to 30, 31 to 40, 41 to 50, 51 to 60, 61 to 70, 71 to 80, 80 to 100, 100 to 150 or 150 to 200, up to 500 or more nts in length, for example.
• the reaction mixture includes the template switch oligonucleotide at a concentration sufficient to permit template switching of the polymerase from the template RNA to the template switch oligonucleotide.
• the template switch oligonucleotide may be added to the reaction mixture at a final concentration of from 0.01 to 100 ⁇ , such as from 0.1 to 10 ⁇ , such as from 0.5 to 5 ⁇ , including 2 to 3 ⁇ .
• the template switch oligonucleotide may include one or more nts (or analogs thereof) that are modified or otherwise non-naturally occurring.
• the template switch oligonucleotide may include one or more nucleotide analogs (e.g., LNA, FANA, 2'-0-Me RNA, 2'-fluoro RNA, or the like), linkage modifications (e.g., phosphorothioates, 3'-3' and 5'-5' reversed linkages), 5' and/or 3' end modifications (e.g., 5' and/or 3' amino, biotin, DIG, phosphate, thiol, dyes, quenchers, etc.), one or more fluorescently labeled nts, or any other feature that provides a desired functionality to the template switch oligonucleotide.
• nucleotide analogs e.g., LNA, FANA, 2'-0-Me RNA, 2'-fluoro RNA, or the
• nucleic acid reagents used when practicing the methods of the present disclosure, including the first strand cDNA primer, the template switch oligonucleotide, the pre-tagmentation primers used for amplifying, e.g., PCR amplifying, the first-strand cDNA to produce the product double stranded cDNA, the post-tagmentation primers used for amplification of tagmentation products, and any combination thereof.
• the template switch oligonucleotide includes a 3' hybridization domain and a 5' pre- tagmentation primer binding domain (which may also be referred to as a second strand synthesis/pre-tagmentation amplification primer binding domain).
• the 3' hybridization domain may vary in length, and in some instances ranges from 2 to 10 nts in length, such as from 3 to 7 nts in length.
• the sequence of the 3' hybridization domain may be any convenient sequence, e.g., an arbitrary sequence, a heterpolymeric sequence (e.g., a hetero-trinucleotide) or homopolymeric sequence (e.g., a homo-trinucleotide, such as G-G-G), or the like.
• a heterpolymeric sequence e.g., a hetero-trinucleotide
• homopolymeric sequence e.g., a homo-trinucleotide, such as G-G-G
• Examples of 3' hybridization domains and template switch oligonucleotides are further described in U.S. Patent No. 5,962,272 and published PCT application publication no. WO2015027135, the disclosures of which are herein incorporated by reference.
• the template switch oligonucleotide can include a pre-tagmentation primer binding domain (i.e., pre-tagmentation primer binding site, which may include a defined nucleotide sequence 5' of the 3' hybridization domain of the template switch oligonucleotide), that enables second strand synthesis and/or amplification, e.g., PCR amplification, of the first strand cDNA product nucleic acid.
• the template switch oligonucleotide may include a sequence, where subsequent to generating the first strand cDNA product nucleic acid, second strand synthesis is performed using a primer that has that sequence.
• the second strand synthesis produces a second strand DNA complementary to the first strand cDNA (i.e., first single product nucleic acid).
• the product nucleic acid may be amplified using a primer pair in which one of the primers has that sequence.
• the template switch oligonucleotide includes a first post-tagmentation (e.g., PCR) primer binding domain, e.g., for use in amplification of a tagemented product, e.g., as described in greater detail below.
• This post-tagmentation primer binding domain may be positioned, e.g., between the pre- tagmentation primer binding domain and the 3' hybridization domain.
• the template switch oligonucleotide includes a modification that prevents the polymerase from switching from the template switch oligonucleotide to a different template nucleic acid after synthesizing the compliment of the 5' end of the template switch oligonucleotide (e.g., a 5' adapter sequence of the template switch oligonucleotide).
• Useful modifications include, but are not limited to, an abasic lesion (e.g., a tetrahydrofuran derivative), a nucleotide adduct, an iso-nucleotide base (e.g., isocytosine, isoguanine, and/or the like), and any combination thereof.
• the template switch oligonucleotide may further include a number of additional components or domains positioned between the 5' and 3' domains described above, such as but not limited to: a first post-tagmentation amplification primer binding domain (e.g., in those embodiments where such a domain is not present on the first strand cDNA synthesis primer), barcode domains, unique molecular identifier domains, a sequencing platform adapter construct domains, etc., where these domains may be as described above.
• a first post-tagmentation amplification primer binding domain e.g., in those embodiments where such a domain is not present on the first strand cDNA synthesis primer
• barcode domains e.g., in those embodiments where such a domain is not present on the first strand cDNA synthesis primer
• unique molecular identifier domains e.g., unique molecular identifier domains
• sequencing platform adapter construct domains e.g., a sequencing platform adapter construct
• the subject methods include combining dNTPs into the reaction mixture.
• each of the four naturally-occurring dNTPs (dATP, dGTP, dCTP and dTTP) are added to the reaction mixture.
• dATP, dGTP, dCTP and dTTP may be added to the reaction mixture such that the final concentration of each dNTP is from 0.01 to 100 mM, such as from 0.1 to 10 mM, including 0.5 to 5 mM (e.g., 1 rtiM).
• At least one type of nucleotide added to the reaction mixture is a non-naturally occurring nucleotide, e.g., a modified nucleotide having a binding or other moiety (e.g., a fluorescent moiety, biotin) attached thereto, a nucleotide analog, or any other type of non- naturally occurring nucleotide that finds use in the subject methods or a downstream application of interest.
• a non-naturally occurring nucleotide e.g., a modified nucleotide having a binding or other moiety (e.g., a fluorescent moiety, biotin) attached thereto, a nucleotide analog, or any other type of non- naturally occurring nucleotide that finds use in the subject methods or a downstream application of interest.
• nucleic acids that find use in practicing the methods of the present disclosure may include any useful nucleotide analogues and/or modifications, including any of the nucleotide analogues and/or modifications described herein.
• the methods include using the product nucleic acid as a template for second-strand synthesis and/or amplification (e.g., for subsequent sequencing of the amplicons).
• the methods include contacting the product nucleic acid with primers that hybridize to the pre-tagmentation amplification primer binding domains, where these domains may be on the ends of the double-stranded cDNA, under amplification conditions, such as PCR amplification conditions, sufficient to produce a product double stranded cDNA.
• a single primer may be used for this step, e.g., where the pre-tagmentation amplification primer binding domains are the same, or different, where the pre-tagmentation amplification primer binding domains are different and first and second amplification primers complementary to different pre-tagmentation amplification primer binding domains are employed.
• Amplification conditions that may be employed include the addition of the one or more primers (e.g., as described above) and dNTPs.
• the conditions may include combining a thermostable polymerase (e.g., a Taq, Pfu, Tfl, Tth, Tli, and/or other thermostable polymerase) - in addition to the template switching polymerase - into the reaction mixture.
• the template switching polymerase may be a thermostable polymerase.
• amplification e.g., amplification with or without further adapter addition
• a single container such as a tube, well, microfluidic chamber, droplet, nanowell, etc.
• the contents of the single container may be placed under conditions suitable for the template switch polymerization reaction to occur (as described elsewhere herein), followed by placing the reaction contents under thermocycling conditions (e.g., denaturation, primer annealing, and polymerization conditions) in which the first-strand cDNA is amplified using primers complementary to the first and second primer binding domains and the thermostable polymerase present in the single container. Due to its thermostability, the thermostable polymerase will retain its activity even when present during the cDNA synthesis phase of this embodiment.
• thermocycling conditions e.g., denaturation, primer annealing, and polymerization conditions
• the first and second amplification primers complementary to the first and second primer binding domains that are employed in this step may vary, and in some instances have the same sequence.
• a sequence/primer of interest is the 5' Primer II A (Takara Bio USA, Inc., Mountain View, CA).
• the first and second amplification primers are both the 5' Primer II A.
• Amplification results in the production of a product double stranded cDNA.
• a method of producing a product double stranded cDNA according to one embodiment of the present disclosure is schematically illustrated in FIG. 2.
• a RNA sample that includes an mRNA is combined with a first strand cDNA primer (in this example, a 3' SMART-Seq CDS Primer IIA), a template switch oligonucleotide (in this example, a SMART-Seq oligonucleotide), a reverse transcriptase (not shown) and dNTPs (not shown).
• a first strand cDNA primer in this example, a 3' SMART-Seq CDS Primer IIA
• a template switch oligonucleotide in this example, a SMART-Seq oligonucleotide
• a reverse transcriptase not shown
• dNTPs not shown
• Non-templated nucleotides are added by the reverse transcriptase when it reaches the 5' end of the mRNA during cDNA synthesis.
• Template switching occurs from the template mRNA to the template switch oligonucleotide which has a 3' hybridization domain complementary to the non-templated nucleotides of the first-strand cDNA.
• the 5' end of the mRNA is captured, allowing for downstream amplification and enrichment of full-length cDNA, e.g., by LD PCR (Long Distance PCR).
• LNA locked nucleic acid
• the components are combined in a reaction mixture under conditions sufficient to produce a double stranded product nucleic acid including a template mRNA and the template switch oligonucleotide each hybridized to adjacent regions of a first strand complementary deoxyribonucleic acid (cDNA).
• cDNA first strand complementary deoxyribonucleic acid
• Product double stranded cDNA is produced by contacting the double stranded product nucleic acid with amplification primers complementary to PCR primer binding domains present in the first strand cDNA primer and template switch oligonucleotide.
• a single species of primer here, PCR Primer IIA
• PCR Primer IIA is capable of amplifying the double stranded product nucleic acid by virtue of the first strand cDNA primer and template switch oligonucleotide each having a PCR primer binding domain complementary to PCR Primer IIA.
• product double stranded cDNA is tagmented with one or more transposomes including a transposase and a transposon nucleic acid, where the transposon nucleic acid includes a transposon end domain for binding to the transposon protein and a second post-tagmentation amplification primer binding domain (e.g., a post-tagmentation PCR amplification primer binding domain), to produce a tagmented sample.
• the second post-tagmentation amplification primer binding domain comprises a NGS read primer domain, e.g., a read primer domain that is different from any read primer domain present in the first-strand cDNA primer, or template switch oligonucleotide.
• Transposomes employed in methods of the present disclosure include a transposase and a transposon nucleic acid that includes a transposon end domain and a post-tagmentation amplification primer binding domain. These domains are defined functionally and so may be one in the same sequence or may be different sequences, as desired. The domains may also overlap, such that part of the post-tagmentation amplification primer binding domain may be present in the transposon end domain.
• transposase means an enzyme that is capable of forming a functional complex with a transposon end domain-containing composition (e.g., transposons, transposon ends, transposon end compositions) and catalyzing insertion or transposition of the transposon end- containing composition into the double-stranded target DNA with which it is incubated in an in vitro transposition reaction.
• Transposases that find use in practicing the methods of the present disclosure include, but are not limited to, Tn5 transposases, Tn7 transposases, and Mu transposases.
• the transposase may be a wild-type transposase.
• the transposase includes one or more modifications (e.g., amino acid substitutions) to improve a property of the transposase, e.g., enhance the activity of the transposase.
• modifications e.g., amino acid substitutions
• hyperactive mutants of the Tn5 transposase having substitution mutations in the Tn5 protein e.g., E54K, M56A and L372P
• Additional Tn5 substitution mutations include, but are not limited to: Y41 H; T47P; E54V, E110K, P242A, E344A, and E345A.
• a given Tn5 mutant may include one or more substitutions, where combinations of substitutions that may be present include, but are not limited to: T47P, M56A and L372P; TT47P, M56A, P242A and L372P; and M56A, E344A and L372P.
• transposon end domain means a double-stranded DNA that consists only of the nucleotide sequences (the "transposon end sequences") that are necessary to form the complex with the transposase or integrase enzyme that is functional in an in vitro transposition reaction.
• a transposon end domain forms a "complex” or a “synaptic complex” or a “transposome complex” or a “transposome composition” with a transposase or integrase that recognizes and binds to the transposon end domain, and which complex is capable of inserting or transposing the transposon end domain into target DNA with which it is incubated in an in vitro transposition reaction.
• the 3'-end of a transferred strand is joined or transferred to target DNA in an in vitro transposition reaction.
• the non-transferred strand which exhibits a transposon end sequence that is complementary to the transferred transposon end sequence, is not joined or transferred to the target DNA in an in vitro transposition reaction.
• the sequence of the particular transposon end domain to be employed when practicing the methods of the present disclosure will vary depending upon the particular transposase employed.
• a Tn5 transposon end domain may be included in the transposon nucleic acid when used in conjunction with a Tn5 transposase.
• the transposon nucleic acid also includes a second post-tagmentation amplification primer binding domain.
• the second post-tagmentation amplification primer binding domain includes a sequencing platform adapter construct domain, e.g., as described above.
• This domain may be a nucleic acid domain selected from a domain (e.g., a "capture site” or “capture sequence”) that specifically binds to a surface- attached sequencing platform oligonucleotide (e.g., the P5 or P7 oligonucleotides attached to the surface of a flow cell in an lllumina® sequencing system), a sequencing primer binding domain (e.g., a domain to which the Read 1 or Read 2 primers of the lllumina® platform may bind), a barcode domain (e.g., a domain that uniquely identifies the sample source of the nucleic acid being sequenced to enable sample multiplexing by marking every molecule from a given sample with a specific barcode or "tag”), a barcode sequencing primer binding domain (a domain to which a primer used for sequencing a barcode binds), a mo
• the sequencing platform adapter construct domain (e.g., which may include post-tagmentation amplification primer binding domain) of the transposon nucleic acid is different from the sequencing platform adapter construct domain (e.g., which may include a post-tagmentation amplification primer binding domain) of the first strand cDNA.
• Such embodiments find use, e.g., where one wishes to produce a library of nucleic acids with one end having one or more sequencing platform adapter sequences and the second end having one or more sequencing platform adapter sequences different from the first end.
• any suitable transposome preparation approach may be used, and such approaches may vary depending upon, e.g., the specific transposase and transposon nucleic acids to be employed.
• the transposon nucleic acids and transposase may be incubated together at a suitable molar ratio (e.g., a 2:1 molar ratio, a 1 : 1 molar ratio, a 1 :2 molar ratio, or the like) in a suitable buffer.
• preparing transposomes may include incubating the transposase and transposon nucleic acid at a 1 : 1 molar ratio in 2x Tn5 dialysis buffer for a sufficient period of time, such as 1 hour.
• the combining and contacting steps described above may be performed in parallel for 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 1 1 or more, 12 or more, 20 or more, 30 or more, 40 or more, 50 or more (e.g., 96), 100 or more, 1000 or more, 10,000, 25,000 or more, 50,000 or more, 100,000 or more, 250,000 or more, 500,000 or more, 1 ,000,000 or more different starting RNA sources, where in some instances the number of different starting RNA sources is 1 ,000,000 or less, such as 500,000 or less, 250,000 or less, 100,000 or less, 50,000 or less, 25,000 or less, 10,000 or less, such as 5,000 or less, including 2,000 or less.
• the different starting RNA sources are single cells (e.g., circulating tumor cells or any other single cells of interest).
• the single cells may be obtained from the same individual or different individuals.
• the different starting RNA sources are RNA samples obtained from different individuals, e.g., different human patients or other human individuals for whom it is desirable to obtain nucleic acid (e.g., RNA or DNA) sequence information.
• the double stranded product cDNAs are tagged during their production with a unique source identifier (e.g., a cell barcode) corresponding to the starting RNA sample from which the product cDNAs were generated. The resultant double stranded product cDNAs produced in parallel may then be pooled prior to tagmentation.
• Such a pooling step may include combining each double stranded product cDNA sample (or aliquots thereof) to be pooled into a single container (e.g., a single tube or other container, e.g., well, microfluidic chamber, droplet, nanowell, etc).
• the pooled cDNA sample is then tagmented, e.g., as described above.
• individual sequencing reads can be traced back to particular starting RNA samples using the source, e.g., cell barcode, enabling multiplexed sequencing. Details regarding barcode-based multiplexed sequencing are described, e.g., in Wong et al. (2013) Curr. Protoc. Mol. Biol. Chapter 7:Unit 7.1 1.
• the methods of preparing NGS libraries are end- capture methods for quantifying RNA (e.g., mRNA transcripts), e.g., for differential expression analysis.
• the end-capture methods capture the 3' ends of RNAs, e.g., where end-capture is facilitated by the presence of a first post-tagmentation amplification primer binding site in the first strand cDNA primer and a second post-tagmentation PCR primer binding site introduced by tagmentation.
• the end-capture methods capture the 5' ends of RNAs, e.g., where end-capture is facilitated by the presence of a first post-tagmentation amplification primer binding site in the template switch oligonucleotide and a 3' second post- tagmentation PCR primer binding site introduced by tagmentation.
• An end-capture NGS library preparation method according to one embodiment of the present disclosure is schematically illustrated in FIG. 3A.
• the method includes combining a RNA sample, a first strand cDNA primer including a first pre-tagmentation amplification primer binding domain, a template switch oligonucleotide including a 3' hybridization domain and a 5' second pre-tagmentation amplification primer binding domain (where both the first and second pre-tagmentation primer binding domains bind to the same primer, in this case "Blocked PCR Primer IIA), a reverse transcriptase (not shown), and dNTPs (not shown), in a reaction mixture under conditions sufficient to produce a double stranded product nucleic acid (not shown) including a template mRNA and the template switch oligonucleotide each hybridized to adjacent regions of a first strand cDNA.
• the reverse transcriptase template switches from the template mRNA to a template switch oligonucleotide (in this example, the Clontech SMART-Seq v4 template switch oligonucleotide) that includes a 3' hybridization domain that includes an LNA and a 5' domain that a second pre-tagmentation amplification primer binding domain.
• a template switch oligonucleotide in this example, the Clontech SMART-Seq v4 template switch oligonucleotide
• the second pre-tagmentation amplification primer binding domain (a domain that binds the Clontech® Primer IIA) is the same as the first pre- tagmentation primer binding domain.
• the cDNA is amplified, e.g., via PCR, using a blocked Clontech® Primer IIA primer to generate product double stranded cDNA (labeled "Double-stranded cDNA" in FIG. 3A).
• the product double stranded cDNA is pooled with one or more other product double stranded cDNA generated in parallel using one or more different RNA samples, e.g., from one or more different single cells.
• the pooling may include combining an aliquot of the product double stranded cDNA with aliquot(s) of one or more other product double stranded cDNA in a single tube or other container, e.g., well, microfluidic chamber, droplet, nanowell, etc.
• transposomes that include a transposase and a transposon nucleic acid including a transposon end domain and one or more second post-tagmentation amplification, e.g., PCR, primer binding domains.
• transposomes including a Tn5 transposase and the lllumina® Nextera® TnRP1 or TnRP2 sequences (where TnRP1 is used as a second post-tagmentation amplification primer binding domain) are used (FIG. 3A, FIG. 1).
• amplification designed for 3' end capture is carried out using post- tagmentation amplification primers that bind to the post-tagmentation amplification, e.g., PCR amplification, primer domains.
• amplification is carried out using a first post- tagmentation amplification primer that includes a post-tagmentation amplification primer binding domain, a first NGS indexing domain and a NGS adapter domain.
• the second post-tagmentation amplification primer binding domain binds to the TnRP1 sequence added to a subpopulation of the pooled product double stranded cDNAs during tagmentation
• the first indexing domain is a forward index sequence
• the NGS adapter domain is the lllumina® P5 sequencing adapter. Only the tagmentation products having the 3' RP2 sequence and a TnRP1 sequence (provided during tagmentation) will be amplified, as shown in FIG. 3A.
• the nucleic acids in the library are suitable for sequencing on an lllumina® sequencing system and include: the P5 adapter sequence; a forward index sequence; the TnRP1 sequence; an insert corresponding to a 3' end of the template mRNA; a source barcode sequence (e.g., corresponding to a single cell or individual, etc.); the RP2 sequence, a reverse index sequence; and a P7 adapter sequence.
• the nucleic acid sequence of such a product is shown in FIG. 3C.
• the method may be used to capture 5' ends of RNAs. Capturing the 5' ends of RNAs finds use, e.g., for 5' end mutation or splice variant analysis, etc. 5' end capture may be carried out, e.g., by including a post- tagmentation primer binding domain (e.g., an RP2 sequence) in the template switch oligonucleotide, rather than in the first strand cDNA primer.
• a post- tagmentation primer binding domain e.g., an RP2 sequence
• post- tagmentation amplification may be carried out using an post-tagmentation amplification primer that binds to the first post-tagmentation primer binding domain domain originally present in the template switch oligonucleotide, in conjunction with a post-tagmentation amplification primer that binds to post-tagmentation primer binding domain, e.g., a TnRP1 or TnRP2 sequence, added during a tagmentation step.
• an post-tagmentation amplification primer that binds to the first post-tagmentation primer binding domain domain originally present in the template switch oligonucleotide
• a post-tagmentation amplification primer that binds to post-tagmentation primer binding domain, e.g., a TnRP1 or TnRP2 sequence, added during a tagmentation step.
• TnRP2 transposomes employed in the example above
• a single type of transposome having a single type of second post-tagmentation amplification, e.g., PCR, primer binding domain
• the assembly of one such modified transposome is schematically illustrated in FIG. 3B, where the Tn5 transposase is shown as solid circles before and after loading with the transposon nucleic acids.
• Amplification of the desired tagmentation products could be carried out using a primer that binds to the single type of post-tagmentation amplification, e.g., PCR, primer binding domain provided by the transposome, in conjunction with a primer that binds to a first post-tagmentation amplification, e.g., PCR, primer binding domain that has been added during an earlier step (e.g., first strand synthesis or amplification of the double stranded product nucleic acid, etc.).
• a primer that binds to the single type of post-tagmentation amplification e.g., PCR, primer binding domain provided by the transposome
• a primer that binds to a first post-tagmentation amplification e.g., PCR, primer binding domain that has been added during an earlier step (e.g., first strand synthesis or amplification of the double stranded product nucleic acid, etc.).
• FIG. 3D schematically illustrates the preparation of a NGS library from an RNA sample according to one embodiment of the present disclosure that employs a single transposome.
• cDNA black
• cDNA black
• a blocked (black star) and modified oligo(dT) first strand cDNA synthesis primer that includes a source barcode, e.g., cell barcode (magenta) and a first post-tagmentation primer binding domain (in this case part of the lllumina read primer 2 sequence (RP2, yellow), positioned between the a 3' poly A domain (black arrow) and a 5' pre-tagmentation amplification primer binding domain (in this case the SMART IIA sequence (green)).
• a source barcode e.g., cell barcode (magenta) and a first post-tagmentation primer binding domain (in this case part of the lllumina read primer 2 sequence (RP2, yellow)
• RP2 lllumina read primer 2 sequence
• the SMART IIA sequence is used as a primer binding domain during pre-tagmentation cDNA amplification
• the lllumina RP2 sequence is used as a primer binding domain during post-tagmentenation library amplification (i.e., it functions as the first post-tagmentation primer binding domain)
• the source barcode e.g., cell barcode
• the process works as follows: first, a reverse transcriptatse (e.g., SMARTScribeTM reverse transcriptase) copies the RNA template by extending from the modified oligo dT primer (CDS primer).
• CDS primer modified oligo dT primer
• the reverse transcriptase switches from the mRNA (blue wavy line) to the SMART-Seq v4 Oligonucleotide (green).
• the full-length cDNA is amplified by PCR with blocked Primer IIA primers that bind to the corresponding pre- tagmentation amplificaiton primer binding domains in the cDNA.
• the presence of the in-line source e.g., cell barcode (magenta)
• the pooled samples are tagmented using a single transposome and the lllumina Nextera read primer 1 sequence is added by the Nextera Tn5 transposon (TnRP1 , orange).
• the 3' ends of the original mRNA are captured by selective PCR amplification with post-tagmentation primers that bind to the RP2 and TnRP1 sequences (which function as the first and second post-tagmentation primer binding domains, respectively).
• post-tagmentation primers that bind to the RP2 and TnRP1 sequences (which function as the first and second post-tagmentation primer binding domains, respectively).
• Other products of the transposon-based reaction are not amplified, either because they lack all the necessary primer binding domains for amplification or because of suppression PCR.
• the nucleic acids in the library are suitable for sequencing on an lllumina® sequencing system and include: the P5 adapter sequence (pink); a forward index sequence (dark blue); the TnRP1 sequence (orang); an insert corresponding to the template mRNA; a source barcode (magenta) (e.g., corresponding to a single cell or individual); the RP2 sequence (yellow), a reverse index sequence (light blue); and a P7 adapter sequence (purple).
• transposomes such as the TnRP1 or TnRP2 transposomes employed in the example above
• 3 or more different types of transposomes may be employed for tagmentation.
• 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 20 or more, 50 or more, or 100 or more different types of transposomes having different post-tagmentation amplification, e.g., PCR, primer binding domains could be employed.
• Tagmentation products of interest in such a tagmented sample may be amplified using a primer that binds to a post-tagmentation amplification, e.g., PCR, primer binding domain of a particular type of transposome, in conjunction with a primer that binds to a post-tagmentation amplification, e.g., PCR, primer binding domain added during an earlier step (e.g., first strand synthesis or amplification of the double stranded product nucleic acid, etc.), such as described above.
• a primer that binds to a post-tagmentation amplification e.g., PCR, primer binding domain of a particular type of transposome
• primer binding domain e.g., primer binding domain added during an earlier step (e.g., first strand synthesis or amplification of the double stranded product nucleic acid, etc.), such as described above.
• the methods include the step of obtaining single cells.
• Obtaining single cells may be done according to any convenient protocol.
• a single cell suspension can be obtained using standard methods known in the art including, for example, enzymatically using trypsin or papain to digest proteins connecting cells in tissue samples or releasing adherent cells in culture, or mechanically separating cells in a sample.
• Single cells can be placed in any suitable reaction vessel in which single cells can be treated individually. For example a 96-well plate, 384 well plate, or a plate with any number of wells such as 2000, 4000, 6000, or 10000 or more-
• the multi-well plate can be part of a chip and/or device.
• the present disclosure is not limited by the number of wells in the multi-well plate, in various embodiments, the total number of wells on the plate is from 100 to 200,000, or from 5000 to 10,000, in other embodiments the plate comprises smaller chips, each of which includes 5,000 to 20,000 wells.
• a square chip may include 125 by 125 nanoweils, with a diameter of 0.1 mm.
• the wells (e.g., nanowells) in the multi-well plates may be fabricated in any convenient size, shape or volume.
• the well may be 100 ⁇ to 1 mm in length, 100 ⁇ to 1 mm in width, and 100 ⁇ to 1 mm in depth.
• each nanoweli has an aspect ratio (ratio of depth to width) of from 1 to 4. in one embodiment, each nanoweli has an aspect ratio of 2.
• the transverse sectional area may be circular, elliptical, oval, conical, rectangular, triangular, polyhedral, or in any other shape. The transverse area at any given depth of the well may also vary in size and shape.
• the wells have a volume of from 0.1 ni to 1 ⁇ .
• the nanoweli may have a volume of 1 ⁇ ! or less, such as 500 ni or less.
• the volume may be 200 nl or less, such as 100 nl or less.
• the volume of the nanoweli is 100 nl.
• the nanoweli can be fabricated to increase the surface area to volume ratio, thereby facilitating heat transfer through the unit, which can reduce the ramp time of a thermal cycle.
• the cavity of each well (e.g., nanoweli) may take a variety of configurations. For instance, the cavity within a well may be divided by linear or curved walls to form separate but adjacent compartments, or by circular walls to form inner and outer annular compartments.
• the wells can be designed such that a single well includes a single cell.
• An individual cell may also be isolated in any other suitable container, e.g., microfluidic chamber, droplet, nanoweli, tube, etc.
• Any convenient method for manipulating single cells may be employed, where such methods include fluorescence activated cell sorting (FACS), robotic device injection, gravity flow, or micromanipulation and the use of semi-automated cell pickers (e.g. the QuixellTM cell transfer system from Stoelting Co.), etc.
• FACS fluorescence activated cell sorting
• robotic device injection e.g. the QuixellTM cell transfer system from Stoelting Co.
• mRNA can be released from the cells by lysing the cells. Lysis can be achieved by, for example, heating or freeze-thaw of the cells, or by the use of detergents or other chemical methods, or by a combination of these. However, any suitable lysis method can be used. A mild lysis procedure can advantageously be used to prevent the release of nuclear chromatin, thereby avoiding genomic contamination of the cDNA library, and to minimize degradation of mRNA. For example, heating the cells at 72°C for 2 minutes in the presence of Tween-20 is sufficient to lyse the cells while resulting in no detectable genomic contamination from nuclear chromatin.
• cells can be heated to 65 °C for 10 minutes in water (Esumi et al., Neurosci Res 60(4):439-51 (2008)); or 70 °C for 90 seconds in PCR buffer II (Applied Biosystems) supplemented with 0.5% NP-40 (Kurimoto et al., Nucleic Acids Res 34(5):e42 (2006)); or lysis can be achieved with a protease such as Proteinase K or by the use of chaotropic salts such as guanidine isothiocyanate (U.S. Publication No. 2007/0281313).
• a protease such as Proteinase K
• chaotropic salts such as guanidine isothiocyanate
• a given single cell workflow may include a pooling step where a cDNA product composition, e.g., made up of synthesized first strand cDNAs or synthesized double stranded cDNAs, is combined or pooled with the cDNA product compositions obtained from one or more additional cells.
• a cDNA product composition e.g., made up of synthesized first strand cDNAs or synthesized double stranded cDNAs
• the number of different cDNA product compositions produced from different cells that are combined or pooled in such embodiments may vary, where the number ranges in some instances from 2 to 50, such as 3 to 25, including 4 to 20 or 10,000, or more.
• the product cDNA composition(s) can be amplified, e.g., by polymerase chain reaction (PCR), such as described above.
• the pooling step can be performed after or before amplification of a cDNA composition produced from a single cell.
• cells are obtained from a tissue of interest and a single-cell suspension is obtained.
• a single cell is placed in one well of a multi- well plate, or other suitable container, such as a microfluidic chamber or tube.
• the cells are lysed and reverse transcription reaction mix is added directly to the lysates without additional purification. It is also possible that the container vessel also contains reverse transcription reagents when the cells are lysed.
• the tagged cDNA samples are pooled and amplified and then sequenced to produce reads. This allows identification of genes that are expressed in each single cell.
• the NGS libraries produced according to the methods of the present disclosure may exhibit a desired complexity (e.g., high complexity).
• the "complexity" of a NGS library relates to the proportion of redundant sequencing reads (e.g., sharing identical start sites) obtained upon sequencing the library. Complexity is inversely related to the proportion of redundant sequencing reads. In a low complexity library, certain target sequences are over-represented, while other targets (e.g., mRNAs expressed at low levels) suffer from little or no coverage.
• the sequencing reads more closely track the known distribution of target nucleic acids in the starting nucleic acid sample, and will include coverage, e.g., for targets known to be present at relatively low levels in the starting sample (e.g., mRNAs expressed at low levels).
• the methods of the present disclosure further include subjecting the NGS library to a NGS protocol.
• the protocol may be carried out on any suitable NGS sequencing platform.
• NGS sequencing platforms of interest include, but are not limited to, a sequencing platform provided by lllumina® (e.g., the HiSeqTM, MiSeqTM and/or NextSeqTM sequencing systems); Ion TorrentTM (e.g., the Ion PGMTM and/or Ion ProtonTM sequencing systems); Pacific Biosciences (e.g., the PACBIO RS II Sequel sequencing system); Life TechnologiesTM (e.g., a SOLiD sequencing system); Roche (e.g., the 454 GS FLX+ and/or GS Junior sequencing systems); or any other sequencing platform of interest.
• lllumina® e.g., the HiSeqTM, MiSeqTM and/or NextSeqTM sequencing systems
• Ion TorrentTM e.g., the Ion PGMTM and/or Ion Prot
• the subject methods may be used to generate a NGS library corresponding to mRNAs for downstream sequencing on a sequencing platform of interest (e.g., a sequencing platform provided by lllumina®, Ion TorrentTM, Pacific Biosciences, Life TechnologiesTM, Roche, or the like).
• a sequencing platform of interest e.g., a sequencing platform provided by lllumina®, Ion TorrentTM, Pacific Biosciences, Life TechnologiesTM, Roche, or the like.
• the subject methods may be used to generate a NGS library corresponding to non-polyadenylated RNAs for downstream sequencing on a sequencing platform of interest.
• microRNAs may be polyadenylated and then used as templates in a template switch polymerization reaction as described elsewhere herein. Random or gene-specific priming may also be used, depending on the goal of the researcher.
• the library may be mixed 50:50 with a control library (e.g., Illumina®'s PhiX control library) and sequenced on the sequencing platform (e.g., an lllumina® sequencing system).
• the control library sequences may be removed and the remaining sequences mapped to the transcriptome of the source of the mRNAs (e.g., human, mouse, or any other mRNA source).
• compositions of embodiments of the invention may include, e.g., one or more of any of the reaction mixture components described above with respect to the subject methods.
• the compositions may include one or more of a RNA (e.g., a control RNA), a polymerase (e.g., a polymerase capable of template-switching, a thermostable polymerase, combinations thereof, or the like), a first-strand cDNA primer having any of the domains described above, a template switch oligonucleotide having any of the domains described above, dNTPs, a salt, a metal cofactor, one or more nuclease inhibitors (e.g., an RNase inhibitor), one or more enzyme- stabilizing components (e.g., DTT), one or more transposome complexes (e.g., containing a first and/or second post-tagmentation amplification binding site) or any other desired reaction mixture component(s).
• a RNA e.g.,
• the subject compositions include a template mRNA and a template switch oligonucleotide each hybridized to adjacent regions of a first strand cDNA, where the first strand cDNA includes: (a) a first post-tagmentation amplification, e.g., PCR, primer binding domain and a first cDNA amplification, e.g., PCR, primer domain 5' of an oligo dT domain; and (b) a second pre-tagmentation amplification, e.g., PCR, primer binding domain at the 3' end of the first strand cDNA.
• the first and second pretagmentation amplification, e.g., PCR, primer binding domains are complementary.
• a tagmented sample produced by tagmenting the above- described double stranded cDNA.
• the tagmenting may be performed with one or more transposomes including a transposase and a transposon nucleic acid that includes a transposon end domain and a second post-tagmentation amplification, e.g., PCR, primer binding domain, to produce a tagmented sample.
• a transposomes including a transposase and a transposon nucleic acid that includes a transposon end domain and a second post-tagmentation amplification, e.g., PCR, primer binding domain
• the composition is present in a reaction tube (e.g., a 0.2 ml_ tube, a 0.6 ml_ tube, a 1.5 ml_ tube, or the like) or a well or microfluidic chamber or droplet or other suitable container.
• a reaction tube e.g., a 0.2 ml_ tube, a 0.6 ml_ tube, a 1.5 ml_ tube, or the like
• the composition is present in two or more (e.g., a plurality of) reaction tubes or wells (e.g., a plate, such as a 96-well plate, a multi-well plate, e.g., containing about 1000, 5000, or 10,000 or more wells).
• the tubes and/or plates may be made of any suitable material, e.g., polypropylene, or the like, PDMS, or aluminium.
• compositions include, e.g., a microfluidic chip (e.g., a "lab-on-a-chip device", e.g., a microfluidic device comprising channels and inlets).
• the composition may be present in an instrument configured to bring the composition to a desired temperature, e.g., a temperature-controlled water bath, heat block, heat block adaptor, or the like.
• the instrument configured to bring the composition to a desired temperature may be configured to bring the composition to a series of different desired temperatures, each for a suitable period of time (e.g., the instrument may be a thermocycler).
• kits may include: a first strand cDNA primer including a 3' oligo dT domain and a 5' first pre-tagmentation amplification primer binding domain; and a template switch oligonucleotide including a 3' hybridization domain and a 5' second pre-tagmentation amplification primer binding domain flanking a first post-tagmentation amplification primer binding domain, e.g., as described above.
• the first and second pre-tagmentation amplification primer binding domains may be identical or different.
• kits may further include one or more transposome including a transposase and a transposon nucleic acid including a transposon end domain and a second post-tagmentation amplification primer binding domain, e.g., as described above.
• the kits may further include pre- tagmentation amplification primers, post-tagmentation amplification primers, etc. Any primers/oligonucleotides provided in the kits may include any of the domains/features described above in the section relating to the methods of the present disclosure.
• kits may further include one or more of a template ribonucleic acid (RNA), components for producing a template RNA from a precursor RNA (e.g., a poly(A) polymerase and associated reagents for polyadenylating a non-polyadenylated precursor RNA), a polymerase (e.g., a polymerase capable of template-switching, a thermostable polymerase, combinations thereof, or the like), dNTPs, a salt, a metal cofactor, one or more nuclease inhibitors (e.g., an RNase inhibitor and/or a DNase inhibitor), one or more molecular crowding agents (e.g., polyethylene glycol, or the like), one or more enzyme-stabilizing components (e.g., DTT), or any other desired kit component(s), such as solid supports, e.g., tubes, beads, microfluidic chips, etc.
• a polymerase e.g., a polymerase
• kits include reagents for isolating RNA from a source of
• RNA may be suitable for isolating nucleic acid samples from a variety of RNA sources including single cells, cultured cells, tissues, organs, or organisms.
• the subject kits may include reagents for isolating a nucleic acid sample from a fixed cell, tissue or organ, e.g., formalin-fixed, paraffin-embedded (FFPE) tissue.
• FFPE paraffin-embedded
• kits may include one or more deparaffinization agents, one or more agents suitable to de-crosslink nucleic acids, and/or the like.
• kits may be present in separate containers, or multiple components may be present in a single container.
• the template switch oligonucleotide and the template switching polymerase may be provided in the same tube, or may be provided in different tubes.
• a subject kits may further include instructions for using the components of the kit, e.g., to practice the subject method.
• the instructions are generally recorded on a suitable recording medium.
• the instructions may be printed on a substrate, such as paper or plastic, etc.
• the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc.
• the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, Hard Disk Drive (HDD), portable flash drive, etc.
• HDD Hard Disk Drive
• the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided.
• An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
• the subject methods find use in a variety of applications, including those that require the presence of particular nucleotide sequences at one or both ends of nucleic acids of interest.
• Such applications exist in the areas of basic research and diagnostics (e.g., clinical diagnostics) and include, but are not limited to, the generation of NGS libraries.
• Such libraries may include adapter sequences that enable sequencing of the library members using any convenient sequencing platform, including: the HiSeqTM, MiSeqTM and NextSeqTM sequencing systems from lllumina®; the Ion PGMTM and Ion ProtonTM sequencing systems from Ion TorrentTM; the PACBIO RS II Sequel sequencing system from Pacific Biosciences, the SOLiD sequencing systems from Life TechnologiesTM, the 454 GS FLX+ and GS Junior sequencing systems from Roche, or any other convenient sequencing platform.
• the methods of the present disclosure find use in generating NGS libraries corresponding to any RNA starting material of interest (e.g., mRNA) and are not limited to polyadenylated RNAs.
• the subject methods may be used to generate NGS libraries from non-polyadenylated RNAs, including microRNAs, small RNAs, siRNAs, and/or any other type non-polyadenylated RNAs of interest.
• the methods also find use in generating strand-specific information, which can be helpful in determining allele- specific expression or in distinguishing overlapping transcripts in the genome.
• An aspect of the subject methods is that - utilizing a template RNA - a cDNA species having sequencing platform adapter sequences at one or both of its ends is generated, e.g., without the added steps associated with traditional approaches for generating hybrid nucleic acid molecules for downstream sequencing applications, such as 5' ligation, washing steps, and any other necessary steps associated with traditional ligation-based approaches. Accordingly, the methods of the present disclosure are more efficient, cost-effective, and provide more flexibility than the traditional approaches.
• Double stranded cDNA was produced according to the example strategy shown in FIG.
• Non- templated nucleotides are added by the reverse transcriptase when it reaches the 5' end of the mRNA during cDNA synthesis.
• Template switching then occurs when a specially designed template-switching oligo (SMART-Seq v4 Oligonucleotide) that has a complementary sequence to these non-templated nucleotides hybridizes to the first-strand cDNA.
• the RT switches from using the mRNA as a template to using the new template for further cDNA synthesis.
• the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing improves upon this method by incorporating locked nucleic acid (LNA) modifications to the template switching oligo and ligation-inhibiting blocks on the priming oligonucleotides, as well as modifications that prevent the polymerase from switching from the template switch oligonucleotide to a different template nucleic acid after synthesizing the compliment of the 5' end of the template switch oligonucleotide (e.g., a 5' adapter sequence of the template switch oligonucleotide).
• LNA locked nucleic acid
• Useful modifications include, but are not limited to, an abasic lesion (e.g., a tetrahydrofuran derivative), a nucleotide adduct, an iso-nucleotide base (e.g., isocytosine, isoguanine, and/or the like), and any combination thereof.
• an abasic lesion e.g., a tetrahydrofuran derivative
• nucleotide adduct e.g., an iso-nucleotide base
• iso-nucleotide base e.g., isocytosine, isoguanine, and/or the like
• FIGS. 4A to 4C show FPKM (Fragments Per Kilobase of exon per Million reads) data indicating that the SMART-Seq v4 kit improves reproducibility for low-input samples.
• cDNA is synthesized by priming with an adapter sequence that includes an oligo dT stretch, designed to prime the reverse transcriptase at the polyA tail. In this way, every mRNA will only have one initiation site, allowing for more accurate quantification of transcript levels.
• the three priming oligos all contained dT30, but they either had: (1) IIA sequence alone, (2) RP2 (lllumina) sequence alone; or (3) the IIA and RP2 sequences - where the IIA sequence was 5' to the RP2 sequence.
• Scenario (1) was identical to the "full length" experiments performed previously, and was used as a control for the highest complexity libraries from single cell equivalent inputs (10 pg total RNA).
• the cDNA was amplified by 17 cycles of cDNA amplification PCR using the IIA sequence.
• Scenario (2) was similar to previous attempts, and resulted in lower complexity libraries, with distributions shifted towards lower molecular weights.
• the cDNA was amplified using both the IIA sequence and the RP2 sequence.
• scenario (1) had a peak at -2500 bp and a yield of 608 pg/ ⁇ .
• Scenario (2) had a peak of -2000 bp and a yield of 335 pg/ ⁇
• scenario (3) had a peak at -2500 bp and a yield of 548 pg/ ⁇ .
• NRC (no RNA control) experiments were performed in parallel. Yields from those reactions were negligible.
• a NGS library was prepared according to the end-capture method schematically illustrated in FIG. 3A. Briefly, cDNA is synthesized with a blocked and modified oligo(dT) primer that adds sequences for subsequent amplification and analysis: a cell barcode; part of the lllumina read primer 2 sequence that is used during library amplification; and the SMART IIA sequence that is used during cDNA amplification.
• the reverse transcriptase (in this exampleSMARTScribeTM reverse transcriptase) copies the template into first strand cDNA by extending from the oligo dT primer. Upon reaching the the 5' end of the template RNA, it switches from the mRNA to the SMART-Seq v4 Oligonucleotide.
• the full-length cDNA is amplified by PCR with blocked Primer IIA oligonucleotides. After PCR, the presence of the barcode allows for pooling of the samples (in this case 12 samples were used, but can adjusted as necessary).
• the pooled samples are tagmented - lllumina Nextera® read primer 1 and 2 sequences are added by the Nextera® Tn5 transposon (TnRP1 and TnRP2).
• the 3' ends of the original cDNA are captured by selective PCR with primers for the TnRP1 and RP2 sequences. In this example, other products of the transposon-based reaction are not amplified, either because they lack all the necessary primer sites for amplification or because of suppression PCR.
• Cluster generation and indexing sequences are added during the library amplification PCR stage to generate a library ready for sequencing on an lllumina platform (e.g., as illustrated FIG. 3C).
• FIG. 5 A flow diagram showing the experimental design for testing the NGS library produced according to the above-described end-capture method is shown in FIG. 5. To test the validity of the pooling strategy, the experiment compared sequencing results from unpooled and pooled libraries. In this experiment, a total of 16 reactions were performed.
• mapping statistics for the pooled and unpooled libraries are shown in FIG. 6.
• the five libraries (four unpooled and one pooled) were sequenced on an lllumina MiSeq® instrument with 150 bp for read 1 and 30 bp for read 2.
• the pooled libraries were de-multiplexed based on the cell barcode sequence from read 2. All libraries were mapped with TopHat v2.0.9 / Bowtie2 v2.1.0 against the mouse genome (mm10) or human genome (hg19).
• the four unpooled libraries are independently labeled (I).
• the reads map to the genome at a high rate (74-89%) with a small proportion mapping to rRNA or mitochondrial regions.
• FIGS. 7A and 7B show graphs indicating normalized read counts per gene as determined by DESeq2 v1.8.1 analysis of mapped libraries. The number of genes identified with different cutoffs (1 , 3, 10, 15, 25, and 30) for normalized read counts are plotted. The data indicates that the present approach enables the identification of a large number of genes from both the pooled and independent samples.
• FIGS. 8A and 8B show heat maps representing the Pearson correlations of regularized log-transformed read-counts (rlog) for libraries derived from mouse brain samples (FIG. 8A) and human brain samples (FIG. 8B). For all comparisons, the correlation (R) was >0.9. Overall, there is no evidence of a correlation bias, indicating that the unpooled samples (I) are not more similar to each other than the pooled samples and vice versa. The data indicates that the libraries are highly correlated regardless of pooling.
• FIGS. 9A and 9B show gene body coverage analysis for unpooled and pooled libraries. Once the reads from each library were mapped to the mouse genome (FIG. 9A) or the human genome (FIG. 9B), gene body coverage analysis was performed to assess the ability of the methods to capture the 3' ends of the cDNA. Across all transcripts (normalized in length to 100%), the majority of reads mapped to the last 20% of the transcripts. There was no difference in 3' coverage between the pooled and unpooled methods, illustrating the accuracy of the selectivity of the second PCR reaction. The four unpooled libraries are labeled independent (I). The data indicates that the present approach enables efficient capture of 3' cDNA ends. III. Single Transposome Mediated NGS Library Preparation
• the embodiment illustrated in FIG 3A utilize transposon complexes which are present with two different adapter sequences, labelled TnRP1 and TnRP2.
• the final amplified library contains only the TnRP1 sequence.
• the method can be performed with using a transposome with only one adapter present, illustrated in FIG 3D.
• cDNA is synthesized with a blocked and modified oligo(dT) primer that adds sequences for subsequent amplification and analysis: a cell barcode; part of the lllumina read primer 2 sequence that is used during library amplification; and the SMART IIA sequence that is used during cDNA amplification.
• single cells were used for each reaction during cDNA synthesis and amplification. Additionally, a single transposome was used during the tagmentation reaction, illustrating the embodiment described above.
• K562 cells were diluted to one cell/ ⁇ in PBS buffer and 1 ⁇ was spotted on a 96-well flat bottom plate. Each spot was inspected via optical microscopy to confirm single cells were present until twelve single cells were isolated, lysed, and subjected to cDNA synthesis according to the protocol illustrated in FIG. 3D.
• the cDNAs were generated with different barcodes on the first strand cDNA primer and could therefore be pooled and purified together. The full length cDNA was analyzed for size and concentration (see FIG. 10A cDNA panel).
• FIG. 10D represents the Pearson correlations of expression levels for the 12 single-cell libraries.
• FIG. 10D shows heat maps representing the Pearson correlations of regularized log-transformed CPM+1 for libraries derived from the K562 single cells. For all comparisons, the correlation (R) was >0.7, while the majority of single-cell libraries are highly correlated (>0.9). The data indicates that the libraries are highly correlated.
• a molecular index (i.e., UMI) is present on the first strand cDNA synthesis primer.
• the UMI is a sequence of six random nucleotides (N, where N can be either A, T, G, or C).
• N can be either A, T, G, or C.
• the CDS primer was synthesized as shown in figure 1 1 B.
• the two mouse brain (MB) derived cDNA was tagmented and amplified as described in FIG. 3A, and the resultant libraries were applied to MiSeq with read 1 of 57 cycles.
• STAR aligner was used for the mapping against the mouse genome.
• the results of mapping are in Table 2, and show that libraries made with or without the presence of the UMI have a high mapping percentage (95-96%), and identify a high number of genes (>10,000 at an expression level of > 0.1 RPKM or > 9,000 at an expression level of > 1 RPKM).
• the percent of reads that are derived from the sense strand of the transcript is also high (99% for both libraries), a metric consistent with the library design.
• a Pearson analysis of the two libraries has a high correlation (0.97), indicating that the presence of the UMI did not change the content of the cDNA library dramatically.
• a method of preparing a next generation sequencing (NGS) library from a ribonucleic acid (RNA) sample comprising:
• a first strand cDNA primer comprising a first pre-tagmentation amplification, e.g., polymerase chain reaction (PCR), primer binding domain;
• PCR polymerase chain reaction
• oligonucleotide each hybridized to adjacent regions of a first strand complementary deoxyribonucleic acid (cDNA), wherein one of the first strand cDNA primer and the template switch oligonucleotide comprises a first post-tagmentation amplification, e.g., PCR, primer binding domain; and
• a second primer comprising a second post-tagmentation amplification, e.g. , PCR amplification, primer domain, a second NGS indexing domain and a second NGS adapter domain;
• each of the first strand cDNA primer and pre-tagmentation primers comprises a 5' polymerase blocking modification.
• At least one of the first strand cDNA primer, template switch oligonucleotide and pre-tagmentation amplification primers comprises one or more nucleotide analogs.
• each of the first strand cDNA primer, template switch oligonucleotide and pre-tagmentation amplification primers comprises one or more nucleotide analogs.
• transposase comprises a Tn5 transposase.
• transposon end domain comprises a Tn5 transposon end domain.
• RNA sample is one that is produced from a single cell.
• the method further comprises subjecting the NGS library to an NGS protocol.
• the method further comprises quantitating one or more RNA species of the RNA sample.
• composition comprising a template mRNA and a template switch
• first post- tagmentation amplification e.g. , PCR, primer binding domain.
• composition according to Claim 25 wherein the first strand cDNA comprises the first post-tagmentation amplification primer binding domain.
• oligonucleotide comprises the first post-tagmentation amplification primer binding domain.
• composition comprising a double stranded cDNA produced from the
• a composition comprising a tagmented sample produced by tagmenting a double stranded cDNA according to Clause 29 with a transposome comprising a transposase and a transposon nucleic acid comprising a transposon end domain and a second post- tagmentation amplification, e.g. , PCR, primer binding domain to produce a tagmented sample.
• a transposome comprising a transposase and a transposon nucleic acid comprising a transposon end domain
• a second post- tagmentation amplification e.g. , PCR, primer binding domain
• DNAs doubled stranded NGS ready deoxyribonucleic acids
• composition according to Clause 31 wherein the sequencing platform adapter constructs comprise adaptor and indexing sequences.
• a kit comprising:
• a first strand cDNA primer comprising an 3' RNA hybridization domain and a 5' first pre-tagmenation amplification, e.g. , PCR amplification, primer binding domain; and a template switch oligonucleotide comprising a 3' hybridization domain and a 5' second pre-tagmentation amplification, e.g. , PCR amplification, primer binding domain; wherein one of the first strand cDNA primer and template switch oligonucleotide further comprises a first post-tagmentation amplification, e.g. , PCR amplification, primer binding domain.
• kit according to any of Clauses 33 to 36, wherein the kit further comprises first and second pre-tagmentation amplification, e.g. , PCR amplification, primers.
• first and second pre-tagmentation amplification e.g. , PCR amplification, primers.
• kit according to any of Clauses 33 to 38, wherein the kit further comprises a transposome comprising a transposase and a transposon nucleic acid comprising a transposon end domain and a second post-tagmentation amplification, e.g. , PCR amplification, primer binding domain.
• a transposome comprising a transposase and a transposon nucleic acid comprising a transposon end domain and a second post-tagmentation amplification, e.g. , PCR amplification, primer binding domain.
• transposase comprises a Tn5 transposase.
• transposon end domain comprises a Tn5 transposon end domain.
• kit according to Clauses 39 to 41 , wherein the kit further comprises:
• a first primer comprising a first post-tagmentation amplification, e.g. , PCR amplification, primer binding domain, a first NGS indexing domain and a first NGS adapter domain; and
• a second primer comprising a second post-tagmentation amplification, e.g. , PCR amplification, primer binding domain, a second NGS indexing domain and a second NGS adapter domain.
• a second post-tagmentation amplification e.g. , PCR amplification, primer binding domain, a second NGS indexing domain and a second NGS adapter domain.
• kit according to any of Clauses 33 to 42, wherein the kit further comprises a solid support. 44. The kit according to any of Clauses 33 to 43, wherein the kit comprises a lyophilized component.

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• Biomedical Technology (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Crystallography & Structural Chemistry (AREA)
• Bioinformatics & Computational Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Plant Pathology (AREA)
• Analytical Chemistry (AREA)
• Immunology (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Applications Claiming Priority (3)

Publications (3)

Family

ID=58289906

Family Applications (1)

Country Status (3)

Families Citing this family (31)

Family Cites Families (5)

• 2016
  • 2016-09-15 EP EP16847330.4A patent/EP3350732B1/de active Active
  • 2016-09-15 WO PCT/US2016/051989 patent/WO2017048993A1/en active Application Filing
  • 2016-09-15 US US15/746,781 patent/US10870848B2/en active Active
• 2020
  • 2020-10-21 US US17/076,568 patent/US11959078B2/en active Active
• 2024
  • 2024-03-12 US US18/602,402 patent/US20240254476A1/en active Pending

Also Published As

Similar Documents

Legal Events